NDV-HXP-S

NDV-HXP-S is a COVID-19 vaccine candidate developed by the Government Pharmaceutical Organization (GPO) of Thailand. It is a protein subunit vaccine that uses a new technology involving the Newcastle Disease Virus (NDV) and the HexaPro (HXP) spike protein of the SARS-CoV-2 virus.

Development and Technology

The NDV-HXP-S vaccine uses a unique technology that combines the Newcastle Disease Virus (NDV) and the HexaPro (HXP) spike protein of the SARS-CoV-2 virus. The NDV is used as a vector to deliver the HXP spike protein into the body. This spike protein then triggers an immune response against the SARS-CoV-2 virus.

The vaccine is being developed by the Government Pharmaceutical Organization (GPO) of Thailand. The GPO is a state enterprise under the Ministry of Public Health that is responsible for the production and distribution of pharmaceutical products in Thailand.

Clinical Trials

The NDV-HXP-S vaccine has undergone several phases of clinical trials. The results of these trials have shown that the vaccine is safe and effective in preventing COVID-19. The vaccine has also been found to be effective against several variants of the SARS-CoV-2 virus.

Availability and Distribution

The NDV-HXP-S vaccine is currently available in Thailand. The GPO has plans to distribute the vaccine to other countries in the future.

See Also

• COVID-19 vaccine
• Newcastle Disease Virus
• HexaPro
• SARS-CoV-2
• Government Pharmaceutical Organization

NDV-HXP-S Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski